Inhibrx Inc (INBX)
34.01
-0.29
(-0.85%)
USD |
NASDAQ |
May 02, 16:00
34.01
0.00 (0.00%)
After-Hours: 20:00
Inhibrx Cash from Investing (TTM): -4.593M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -4.593M |
September 30, 2023 | -1.418M |
June 30, 2023 | -0.587M |
March 31, 2023 | -0.592M |
December 31, 2022 | -0.686M |
September 30, 2022 | -0.686M |
June 30, 2022 | -0.875M |
March 31, 2022 | -0.912M |
December 31, 2021 | -0.809M |
September 30, 2021 | -1.154M |
Date | Value |
---|---|
June 30, 2021 | -1.284M |
March 31, 2021 | -1.287M |
December 31, 2020 | -1.364M |
September 30, 2020 | -1.087M |
June 30, 2020 | -1.499M |
March 31, 2020 | -1.824M |
December 31, 2019 | -1.81M |
September 30, 2019 | -1.986M |
June 30, 2019 | -1.35M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-4.593M
Minimum
Dec 2023
-0.587M
Maximum
Jun 2023
-1.358M
Average
-1.284M
Median
Jun 2021
Cash from Investing (TTM) Benchmarks
Axonics Inc | 20.63M |
NovaBay Pharmaceuticals Inc | -0.019M |
Palatin Technologies Inc | 9.293M |
iBio Inc | 8.285M |
Theriva Biologics Inc | -0.202M |